A. Hackett

Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

H. Beltran, S. Vallabhajosula, N. Bander, 2019, Annals of Oncology.

Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies

O. Elemento, H. Beltran, N. Bander, 2019, Clinical Research (Excluding Clinical Trials).

Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).

N. Bander, J. Osborne, P. Christos, 2019, Journal of Clinical Oncology.

Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.

O. Elemento, A. Sboner, H. Beltran, 2019, Journal of Clinical Oncology.

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2018 .

Antibody-Drug Conjugates in Bladder Cancer

P. Vlachostergios, S. Tagawa, C. Jakubowski, 2018, Bladder cancer.